Payment overview · 2025
General Payments
$357.14
12 reported records · 6 companies
Healthcare provider profile · identity verified
Amanda Magrini, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPARKS, NV · NPI 1760706519
Verified facts
What the public records show
CMS Open Payments records show Amanda Magrini, MD received $357.14 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $101.46 | 28.4% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $100.00 | 28.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $52.75 | 14.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.05 | 13.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.52 | 9.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.36 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $357.14 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $101.46 | 4 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $52.75 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.52 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.52 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 560 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 515 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 305 | 86 |
| Lisinopril | Lisinopril | 275 | 79 |
| Losartan Potassium | Losartan Potassium | 272 | 80 |
| Omeprazole | Omeprazole | 243 | 67 |
| Gabapentin | Gabapentin | 216 | 63 |
| Trazodone Hcl | Trazodone Hcl | 214 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 51 |
| Sertraline Hcl | Sertraline Hcl | 198 | 49 |
| Metformin Hcl Er | Metformin Hcl | 197 | 55 |
| Alprazolam | Alprazolam | 181 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 48 |
| Simvastatin | Simvastatin | 143 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 38 |
| Furosemide | Furosemide | 123 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 25 |
| Meloxicam | Meloxicam | 107 | 38 |
| Metformin Hcl | Metformin Hcl | 104 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 27 |
| Ibuprofen | Ibuprofen | 99 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 32 |
| Eliquis | Apixaban | 89 | 20 |
| Tramadol Hcl | Tramadol Hcl | 88 | 14 |
| Allopurinol | Allopurinol | 87 | 26 |
| Potassium Chloride | Potassium Chloride | 86 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 27 |
| Jardiance | Empagliflozin | 82 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 11 |
| Ozempic | Semaglutide | 78 | 15 |
| Alendronate Sodium | Alendronate Sodium | 77 | 23 |
| Atenolol | Atenolol | 75 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 20 |
| Montelukast Sodium | Montelukast Sodium | 73 | 18 |
| Estradiol | Estradiol | 72 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 12 |
| Lorazepam | Lorazepam | 69 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 66 | 22 |
| Mounjaro | Tirzepatide | 61 | 11 |
| Pregabalin | Pregabalin | 60 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 20 |
| Aripiprazole | Aripiprazole | 59 | suppressed |
| Synthroid | Levothyroxine Sodium | 57 | 16 |
| Carvedilol | Carvedilol | 56 | 22 |
| Clobetasol Propionate | Clobetasol Propionate | 55 | 14 |
| Celecoxib | Celecoxib | 54 | 11 |
| Famotidine | Famotidine | 53 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 17 |
| Trulicity | Dulaglutide | 53 | 14 |
| Lidocaine | Lidocaine | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 12 |
| Spironolactone | Spironolactone | 49 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 38 |
| Lovastatin | Lovastatin | 47 | 14 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 16 |
| Acyclovir | Acyclovir | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | 14 |
| Ondansetron Odt | Ondansetron | 43 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 41 | 36 |
| Glipizide | Glipizide | 39 | suppressed |
| Glipizide Er | Glipizide | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 12 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 13 |
| Valacyclovir | Valacyclovir Hcl | 34 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 11 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Cephalexin | Cephalexin | 28 | 22 |
| Linzess | Linaclotide | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Buprenorphine | Buprenorphine | 18 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $357.14 · 12 records | ABBVIE INC. | ABRYSVO, COMIRNATY, MOUNJARO, NURTEC ODT, PREVNAR 20, REXULTI, SAPIEN 3 Ultra RESILIA, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error